ASCO GI 2022

Oesophageal and Gastric Cancer

EMR versus ESD in oesophageal cancer

Presented By

Dr Vani Konda, Baylor University Medical Center, TX, USA

Conference

ASCO GI 2022

21 March, 2022 11:23

Pre-operative chemoradiation versus peri-operative chemotherapy for oesophageal cancer

Presented By

Prof. Karyn Goodman, Icahn School of Medicine at Mount Sinai, NY, USA

Conference

ASCO GI 2022

21 March, 2022 11:22

AK104 plus chemotherapy promising first-line option for gastric cancer

Presented By

Dr Jiafu Ji, Beijing Cancer Hospital, China

Trial

Phase 1/2, AK104-201

Conference

ASCO GI 2022

21 March, 2022 11:19

DESTINY-Gastric01: OS benefit of T-DXd over chemotherapy for HER2-positive gastric cancer

Presented By

Dr Kensei Yamaguchi, Cancer Institute Hospital of JFCR, Japan

Trial

Phase 2, DESTINY-Gastric01

Conference

ASCO GI 2022

21 March, 2022 11:17

The emerging role of AI in gastroesophageal cancer

Presented By

Dr Wai Leung, University of Hong Kong, China

Conference

ASCO GI 2022

21 March, 2022 11:15

DCF outperforms standard-of-care for locally advanced oesophageal cancer

Presented By

Dr Ken Kato, National Cancer Center Hospital, Japan

Trial

Phase 3, JCOG1109, NExT

Conference

ASCO GI 2022

21 March, 2022 11:13

Nivolumab in gastric cancer: Efficacy update and the role of gut microbiome

Presented By

Dr Kohei Shitara, National Cancer Center Hospital East, Japan; Dr Yu Sunakawa, St. Marianna University School of Medicine, Japan

Trial

Phase 3, CheckMate 649, DELIVER

Conference

ASCO GI 2022

21 March, 2022 11:11

Updates on pembrolizumab for oesophageal and gastric cancer

Presented By

Dr Jean-Philippe Metges, CHU Brest, France; Dr Zev Wainberg, University College Los Angeles, CA, USA

Trial

Phase 3, KEYNOTE-590, KEYNOTE-062

Conference

ASCO GI 2022

21 March, 2022 11:08

Anal and Colorectal Cancer

NIPICOL: New data on optimal ICI treatment duration in MSI/dMMR mCRC

Presented By

Dr Romain Cohen, Sorbonne University, France

Trial

Phase 2, NIPICOL

Conference

ASCO GI 2022

21 March, 2022 10:30

Dostarlimab may offer an alternative for dMMR rectal cancer

Presented By

Dr Melissa Lumish, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 2

Conference

ASCO GI 2022

21 March, 2022 10:28

DESTINY-CRC01: Maintained efficacy of T-DXd in mCRC

Presented By

Dr Takayuki Yoshino, National Cancer Center Hospital East, Japan

Trial

Phase 2, DESTINY-CRC01

Conference

ASCO GI 2022

21 March, 2022 10:26

Key updates in colorectal cancer screening

Presented By

Dr Robin Mendelsohn, Memorial Sloan Kettering Cancer Center, NY, USA

Conference

ASCO GI 2022

21 March, 2022 10:25

Impact of COVID-19 on screening for colorectal cancer

Presented By

Dr John Carethers, University of Michigan, MI, USA

Conference

ASCO GI 2022

21 March, 2022 10:23

Nivolumab plus standard-of-care does not meet primary endpoint for mCRC

Presented By

Dr Heinz-Josef Lenz, USC Norris Comprehensive Cancer Center, CA, USA

Trial

Phase 3, CheckMate 9X8

Conference

ASCO GI 2022

21 March, 2022 10:21

No benefit of additional oxaliplatin in elderly patients with mCRC

Presented By

Dr Tetsuya Hamaguchi, National Cancer Center, Japan

Trial

Phase 3, JCOG1018, RESPECT

Conference

ASCO GI 2022

21 March, 2022 10:19

Prognostic impact of early oxaliplatin discontinuation in colon cancer unravelled

Presented By

Dr Claire Gallois, Université de Paris, France

Conference

ASCO GI 2022

21 March, 2022 10:17

Long-course chemoradiation versus short-course radiotherapy in rectal cancer

Presented By

Dr Emma Holliday, MD Anderson Cancer Center, University of Texas, TX, USA

Conference

ASCO GI 2022

21 March, 2022 10:15

Analysis of metastasectomy in CRC reveals benefits and disparities

Presented By

Dr Jude Khatib (University of Texas, TX, USA

Conference

ASCO GI 2022

21 March, 2022 10:12

EPOCH trial: Subgroup analyses and additional endpoints for TARE plus chemo

Presented By

Dr William Harris, Seattle Cancer Care Alliance, WA, USA

Trial

Phase 3, EPOCH

Conference

ASCO GI 2022

21 March, 2022 10:09

Hepatobiliary Cancer

Adjuvant S-1 therapy superior to observation in resected biliary tract cancer

Presented By

Dr Masafumi Ikeda, Japan Clinical Oncology Group, Japan

Trial

Phase 3, JCOG1202, ASCOT

Conference

ASCO GI 2022

21 March, 2022 10:13

Pembrolizumab safe and efficacious in advanced hepatocellular carcinoma

Presented By

Prof. Shukui Qin, Nanjing University of Chinese Medicine, China

Trial

Phase 3, KEYNOTE-394

Conference

ASCO GI 2022

21 March, 2022 10:11

TOPAZ-1: Adding durvalumab to chemotherapy effective in advanced biliary tract cancer

Presented By

Dr Do-Youn Oh, Seoul National University College of Medicine, South Korea

Trial

Phase 3, TOPAZ-1

Conference

ASCO GI 2022

21 March, 2022 10:09

HIMALAYA: Durvalumab ± tremelimumab new first-line option for unresectable HCC

Presented By

Prof. Ghassan Abou-Alfa, Memorial Sloan Kettering Center, NY, USA

Trial

Phase 3, HIMALAYA

Conference

ASCO GI 2022

21 March, 2022 10:05

LAUNCH: TACE plus lenvatinib efficacious in advanced HCC

Presented By

Prof. Ming Kuang, Sun Yat-sen University, China

Trial

Phase 3, LAUNCH

Conference

ASCO GI 2022

21 March, 2022 10:03

Modest activity of atezolizumab plus bevacizumab in Child-Pugh B HCC

Presented By

Dr Hyeyeong Kim, Ulsan University Hospital, South Korea

Trial

Phase 3, IMbrave150

Conference

ASCO GI 2022

21 March, 2022 10:00

Pancreatic Cancer